HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Safety Review For Upset Stomach, Hangover OTCs Reconsiders Science

This article was originally published in The Pink Sheet

Executive Summary

The US Nonprescription Drugs and Drug Safety and Risk Management advisory committees will discuss the safety of using OTC analgesic combination products for upset stomach and hangover even though Drug Facts labels already warn about the risk of serious bleeding.

You may also be interested in...



OTC Hangover Remedy Safety On Tap For FDA Advisory Committees

CDER schedules an NDAC and DSRMAC joint meeting while also negotiating with industry stakeholders on a potential proposal for a user fee program to support FDA’s work on finalizing monographs or amending monographs with additional ingredients or indications.

OTC Antacid/Aspirin Bleeding Risk Raises Concerns At CDER

CDER publishes a Drug Safety Communication, a consumer announcement and a MedWatch notice warning about the risk of serious bleeding when using OTC aspirin-containing antacid products.

“No End In Sight” For Completing OTC Monographs – CDER Director Woodcock

Janet Woodcock says FDA expected when the process was launched to complete all monographs by the year 2000, but 25 remain in tentative final monograph status, with a rulemaking required to finalize each one. “The rulemaking process … doesn’t work for getting monographs done in a very timely manner,” she says.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122741

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel